BioSim™ anti-Denosumab (Prolia®) (Human) ELISA Kit
- Usually Shipped in 5 Working Days
- 100 Assays
- Storage Conditions:
- Shipping Conditions:
- Gel Pack
- Shelf life:
- 12 months
Denosumab (Prolia®) is a human monoclonal antibody that binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Denosumab ELISA kit is designed to detect antibody against Denosumab with high specificity and sensitivity in biological matrices.
Alternate Name: N/A
Tag Line: A Sandwich ELISA kit for the qualitative determination of antibody against Denosumab in human serum or plasma.
Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- qualitative determination of antibody against Denosumab (Prolia) in human serum and plasma
Detection Method: Absorbance (450 nm)
Sample Type: Human serum and plasma
Species Reactivity: Human
Applications: This ELISA kit is used for Qualitative determination of antibody against Denosumab (Prolia) in serum and plasma
Features & Benefits: Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Denosumab (Prolia) in human serum and plasma. Cross Reactivity: Denosumab (Prolia) infusion camouflages/masks the presence of antibody to Etanercept (ATC) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATC. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Denosumab.